Citations

Mayo Clinic

Showing 10 of 108599 citations.

Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options
Gay, Laurie M. , Kim, Sungeun , Fedorchak, Kyle, Kundranda, Madappa N. , Odia, Yazmín , Nangia, Chaitali, Battiste, James , Colón‐Otero, Gerardo , Powell, Steven , Elvin, Julia A. , Vergilio, Jo-Anne, Suh, James , Ali, Siraj M. , Stephens, Philip J., Miller, Vincent A. , Russell, Jeffery Scott , Elvin, Julia A , Vergilio, Jo‐Anne, Ross, Jeffrey S , Odia, Yazmin

The Oncologist | May 12, 2017 | Volume: 22 | Issue: 7 | Pages: 834-842

10.1634/theoncologist.2016-0287 | PMID 28495808 Get It

Abstract Background Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant neoplasm of the olfactory mucosa. Despite surgical resection combined with radiotherapy and adjuvant chemotherapy, ENB often relapses with rapid progression. Current multimodality, nontargeted therapy for relapsed ENB is of limited clinical benefit. Materials and Methods We queried whether comprehensive genomic profiling (CGP) of relapsed or refractory ENB can uncover genomic alterations (GA) that could identify potential targeted therapies for these patients. CGP was performed on formalin-fixed, paraffin-embedded sections from 41 consecutive clinical cases of ENBs using a hybrid-capture, adaptor ligation based next-generation sequencing assay to a mean coverage depth of 593X. The results were analyzed for base substitutions, insertions and deletions, select rearrangements, and copy number changes (amplifications and homozygous deletions). Results Clinically relevant GA (CRGA) were defined as GA linked to drugs on the market or under evaluation in clinical trials. A total of 28 ENBs harbored GA, with a mean of 1.5 GA per sample. Approximately half of the ENBs (21, 51%) featured at least one CRGA, with an average of 1 CRGA per sample. The most commonly altered gene was TP53 (17%), with GA in PIK3CA, NF1, CDKN2A, and CDKN2C occurring in 7% of samples. Conclusion We report comprehensive genomic profiles for 41 ENB tumors. CGP revealed potential new therapeutic targets, including targetable GA in the mTOR, CDK and growth factor signaling pathways, highlighting the clinical value of genomic profiling in ENB.
Morbidity and Mortality Associated With Balloon Aortic Valvuloplasty
Zack, Chad, Sarraf, Mohammad , Bashir, Riyaz , Nishimura, Rick A., Eleid, Mackram F. , Sandhu, Gurpreet S. , Gulati, Rajiv , Greason, Kevin L. , Holmes, David R. , Rihal, Charanjit S. , Zack, Chad J, Alkhouli, Mohamad , Nkomo, Vuyisile T. , Rihal, Charanjit S.

Circulation: Cardiovascular Interventions | May 12, 2017 | Volume: 10 | Issue: 5 | Pages: No page available

10.1161/circinterventions.116.004481 | PMID 28495894 Get It

Background— The introduction of transcatheter aortic valve replacement (TAVR) led to renewed interest in balloon aortic valvuloplasty (BAV). We sought to assess contemporary trends in BAV utilization and their outcomes. Methods and Results— The Nationwide Inpatient Sample was used to identify patients who underwent BAV between 2004 and 2013. In-hospital morbidity and mortality, and predictors of death after BAV were assessed. Outcomes of propensity-matched groups of patients undergoing elective BAV or TAVR were evaluated. BAV utilization increased from 707 cases in 2004 to 3715 cases in 2013 (national estimates). Procedural and in-hospital mortality were 1.4% and 8.5%, respectively. Vascular complications occurred in 7.0% of cases, blood transfusion in 17.5%, clinical stroke in 1.8%, and pacemaker implantation in 3.0%. The strongest predictors of in-hospital death were cardiogenic shock (odds ratio, 6.01; 95% confidence interval, 4.19–8.61; P <0.001), need for left ventricular assist device (odds ratio, 3.48; 95% confidence interval, 2.25–5.36; P <0.001), coagulopathy (odds ratio, 2.19; 95% confidence interval, 1.51–3.18; P <0.001), and low institutional volume of BAV (odds ratio, 1.58; 95% confidence interval, 1.06–2.37; P =0.03). In propensity-matched patients undergoing elective BAV or TAVR, rates of in-hospital mortality (2.9% versus 3.5%; P =0.60), clinical stroke (1.6% versus 3.1%; P =0.10), and vascular complications (8.2% versus 10.9%; P =0.14) were similar. However, BAV was associated with lower rates of pacemaker implantation (2.9% versus 8.0%; P <0.001) and blood transfusion (12.8% versus 22.9%; P <0.001). Conclusions— In a contemporary national registry, BAV is associated with significant morbidity and mortality that are similar to TAVR. With the substantial increase in BAV utilization and the continuous improvement in TAVR outcomes, these data have important implications to aid clinicians in the selection of appropriate BAV candidates.
Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP‐825 Breath Powered ® Exhalation Delivery System (Sumatriptan Nasal Powder) vs Ora
Silberstein, Stephen D., Winner, Paul, McAllister, Peter J., Tepper, Stewart J. , Halker, Rashmi, Mahmoud, Ramy , Siffert, João

Headache: The Journal of Head and Face Pain | May 12, 2017 | Volume: 57 | Issue: 6 | Pages: 862-876

10.1111/head.13105 | PMID 28497569 Get It

Objective To further characterize the clinical utility of AVP‐825 based on additional prespecified outcomes and post hoc analyses of COMPASS, a Phase 3 comparative efficacy trial of AVP‐825 vs 100 mg oral sumatriptan (NCT01667679). AVP‐825 was approved in January 2016 by the US Food and Drug Administration under the name ONZETRA ® Xsail ® (sumatriptan nasal powder) for the acute treatment of migraine with or without aura in adults. Background AVP‐825 is a delivery system that uses a patient's own breath to deliver low‐dose sumatriptan powder to the upper posterior regions of the nasal cavity beyond the narrow nasal valve, areas lined with vascular mucosa conducive to rapid drug absorption into the systemic circulation. The recommended dose of AVP‐825 is 22 mg sumatriptan powder administered as one 11 mg nosepiece in each nostril, which delivers approximately 15‐16 mg of sumatriptan intranasally. The COMPASS trial compared AVP‐825 22‐100 mg oral sumatriptan across multiple migraine attacks for efficacy, safety, and tolerability endpoints. Design/Methods COMPASS was a randomized, multicenter, double‐dummy, crossover, multiattack, comparative efficacy study with two 12‐week double‐blind periods. Patients with 2‐8 migraine attacks/month were randomized 1:1 to AVP‐825 (22 mg) plus oral placebo or an identical placebo delivery system plus 100 mg oral sumatriptan for the first period, and then patients switched treatments for the second period. Patients treated up to 5 qualifying migraines per period within 1 h of onset, even if the intensity of the attack was mild. Results from the primary endpoint (SPID‐30, defined as the sum of pain intensity differences from dosing to 30 minutes), key secondary efficacy endpoints and safety assessments have been reported in the primary publication (Tepper et al., 2015). This article reports additional prespecified outcomes, including the SPID‐30 for attacks treated when baseline severity was mild vs moderate/severe, measures of sustained response and consistency of effect in patients who experienced multiple migraine attacks, and the results of post hoc analyses performed to assess total migraine freedom (defined as no pain and no migraine‐associated symptoms, including nausea, vomiting, photophobia, and phonophobia), time to pain freedom, time to meaningful pain relief, and local (occurring at the site of administration in the nose) vs systemic treatment‐emergent adverse events (TEAEs). Results A total of 185 patients completed both treatment periods, yielding 1,531 migraine attacks which were treated and assessed (765 AVP‐825, 766 oral sumatriptan). Treatment with AVP‐825 provided greater reduction in migraine pain intensity which was statistically significant vs oral sumatriptan in the first 30 minutes postdose regardless of whether attacks were treated when pain was mild (least squares mean SPID‐30 = 3.90 vs 0.24, P = .0013) or moderate/severe (least squares mean SPID‐30 = 13.83 vs 10.07, P = .0002). At every time point from 15 to 90 minutes postdose, the proportion of attacks achieving total migraine freedom was greater and statistically significant after treatment with AVP‐825 vs 100 mg oral sumatriptan. AVP‐825 treatment resulted in greater odds of achieving pain freedom (odds ratio, OR = 1.29, P < .01) and meaningful pain relief (OR = 1.32, P < .0001), which were also statistically significant compared with oral sumatriptan. In addition, a greater proportion of attacks treated with AVP‐825 vs oral sumatriptan was associated with sustained pain freedom, achieving statistical significance when assessed from 1 h postdose through 24 hours postdose (33.3% vs 27.9%; P < .05) and through 48 hours postdose (32.7% vs 27.4%; P < .05). For patients who treated multiple migraine attacks in both treatment periods, a greater proportion had consistent pain relief and pain freedom following treatment with AVP‐825 compared to oral sumatriptan across multiple attacks, a difference that achieved statistical significance at 30 minutes postdose. Local TEAEs of abnormal taste and nasal discomfort were more common following AVP‐825 treatment. Of the patients experiencing either of these TEAEs, about 90% described the intensity as mild, and only one discontinued treatment because of either of these two TEAEs. Conclusions These results from the COMPASS study further demonstrate that treatment with AVP‐825 provides earlier onset and more consistent across‐episode improvement of pain and migraine‐associated symptoms compared with oral sumatriptan, highlighting the clinical advantages of this newly approved intranasal delivery system for low‐dose sumatriptan powder.
Management of Chronic Pain in the Aftermath of the Opioid Backlash
Kroenke, Kurt , Cheville, Andrea

JAMA | May 11, 2017 | Volume: 317 | Issue: 23 | Pages: 2365

10.1001/jama.2017.4884 | PMID 28494058 Get It

Elsberg syndrome
Savoldi, Filippo , Flanagan, Eoin P. , Toledano, Michel , Weinshenker, Brian G. , Kaufmann, Timothy J. , Flanagan, E P , Weinshenker, Brian G

Neurology Neuroimmunology & Neuroinflammation | May 11, 2017 | Volume: 4 | Issue: 4 | Pages: No page available

10.1212/nxi.0000000000000355 | PMID 28534040 Get It

An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease
Martin, Paul J. , Storer, Barry E. , Inamoto, Yoshihiro , Carpenter, Paul A. , Pidala, Joseph, Palmer, Jeanne , Arora, Mukta , Jagasia, Madan , Arai, Sally , Lee, Stephanie J. , Flowers, Mary E.D. , Cutler, Corey S. , Lee, Stephanie J

Blood | May 11, 2017 | Volume: 130 | Issue: 3 | Pages: 360-367

10.1182/blood-2017-03-775767 | PMID 28495794 Get It

Key Points Complete or partial response at 1 year without secondary systemic treatment provides clinical benefit in patients with chronic GVHD. Success defined by this endpoint is currently observed in fewer than 20% of patients after initial systemic treatment of chronic GVHD.
Peripheral nerve blocks for hip fractures
Guay, Joanne, Parker, Martyn J. , Griffiths, R. , Kopp, Sandra L. , Kopp, Sandra

Cochrane Database of Systematic Reviews | May 11, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/14651858.cd001159.pub2 | PMID 28494088 Get It

Antiepileptic drug therapy in patients with autoimmune epilepsy
Feyissa, Anteneh M. , López‐Chiriboga, A. Sebastian , Britton, Jeffrey W. , Feyissa, A M

Neurology Neuroimmunology & Neuroinflammation | May 11, 2017 | Volume: 4 | Issue: 4 | Pages: No page available

10.1212/nxi.0000000000000353 | PMID 28680914 Get It